1 Title Page, Original Research

2

3 A Phase1 Results of a Non-Stabilized Spike-Encoding mRNA Vaccine in Adults

- 4 Authors:
- 5 Sivaporn Gatechompol*, MD, School of Global Health, and Center of Excellence in tuberculosis,
- 6 Faculty of Medicine, Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research
- 7 Centre
- 8 Wonngarm Kittanamongkolchai*, MD, Clinical Research Center (Chula CRC), Faculty of
- 9 Medicine, Chulalongkorn University
- 10 Chutitorn Ketloy, Ph.D., Center of Excellence in Vaccine Research and Development, and
- 11 Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Thailand
- 12 Eakachai Prompetchara, Ph.D., Center of Excellence in Vaccine Research and Development, and
- 13 Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Thailand
- 14 Arunee Thitithanyanont, MD, Department of Microbiology, Faculty of Science, Mahidol
- 15 University, Bangkok, Thailand
- 16 Anan Jongkaewwattana, Ph.D., Virology and Cell Technology Research Team, National Center
- 17 for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology
- 18 Development Agency (NSTDA), Thailand
- 19 Supranee Buranapraditkun, Ph.D., Center of Excellence in Vaccine Research and Development,
- 20 and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Thailand
- 21 Mohamad-Gabriel Alameh, Ph.D., Perelman School of Medicine, University of Pennsylvania,
- 22 USA

23	Sasiwimol Uboly	/am, Ph.D.,	Clinical Research	Laboratory/HIV-NAT	laboratory,	Chula CRC,	Faculty
----	-----------------	-------------	--------------------------	--------------------	-------------	------------	---------

- 24 of Medicine; and HIVNAT, Thai Red Cross AIDS Research Centre, Thailand
- 25 Jiratchaya Sophonphan, M.Sc., Biostatistics Unit, HIVNAT, Thai Red Cross AIDS Research Centre,
- 26 Thailand
- 27 Tanakorn Apornpong, M.Sc., Biostatistics Unit, HIVNAT, Thai Red Cross AIDS Research Centre,
- 28 Thailand
- 29 Stephen Kerr, Ph.D., Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn
- 30 University, Bangkok, Thailand
- 31 Adeeba Kamarulzaman, MD, Faculty of Medicine, University of Malaya, Malaysia
- 32 Sarawut Siwamogsatham, MD, Clinical Research Center (Chula CRC), Faculty of Medicine,
- 33 Chulalongkorn University
- 34 Eugène Kroon, MD, Institute of HIV Research and Innovation (IHRI), Bangkok, Thailand
- 35 Thanyawee Puthanakit, MD, Department of Pediatrics, and Center of Excellence in Pediatric
- 36 Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok,

37 Thailand

- 38 Kanitha Patarakul, MD, Chula Vaccine Research Center (Chula VRC), and Department of
- 39 Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- 40 Tanapat Palaga, Ph.D., Chula Vaccine Research Center (Chula VRC), Faculty of Medicine; and
- 41 Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand
- 42 Wassana Wijagkanalan, Ph.D., Bionet Asia, Co. Ltd., Ayutthaya, Thailand
- 43 Drew Weissman**, MD, Perelman School of Medicine, University of Pennsylvania, USA

- 44 Kiat Ruxrungtham^{**}, MD, Center of Excellence in Vaccine Research and Development
- 45 (ChulaVRC), Department of Medicine; and School of Global Health, Faculty of Medicine,
- 46 Chulalongkorn University, Thailand
- 47 and ChulaVAC-001 study team.
- 48
- 49 *Contributed equally as first author
- 50 ******Contributed equally as senior author
- 51
- 52 **Corresponding author**
- 53 Kiat Ruxrungtham, MD
- 54 Center of Excellence in Vaccine Research and Development (ChulaVRC)
- 55 Faculty of Medicine, Chulalongkorn University
- 56 10th Floor, Aor Por Ror Building,
- 57 1873 Rama IV Road, Pathumwan, Bangkok 10330
- 58 Thailand
- 59 telephone: +66 2 256 4000 ext. 3563
- 60 e-mail: kiat.r@chula.ac.th
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 00
- 69

70 71 **Graphical Abstract** 72 73 ChulaCov19 mRNA Vaccine Phase 1 Dose escalating Study **10, 25** or **50 μ**g IM x 2 dos Safety and Tolerability • No SAEs, both local and systemic AEs are dose dependent 3 weeks apart Majority of AEs were mild to moderate and transient ٠ ChulaCov19 r A/LNP • More common after Dose 2 and less common in Elderly. Aged 18-55 and 56-75 years 1-stabilized Encoding for Wild Ty; N=36 per age group SAR-Cov2S-spike-protein Immunogenicity Results: Elicited strong SARS-Cov2 specific antibodies and T-cell Responses Live-Virus Neutralizing Antibody against Wild Type (microVNT50) Adults (aged 18-55 years) Elderly (aged 56-75 years) 10,000 Adults (aged 18-55 years) Elderly (aged 56-75 years) 10,000 10 µg 50 µg 25 µg 50 µg 10 µg 25 µg IFN-' spot forming cells/10⁶ PBMCs (Geometric mean) Reciprocal microVNT50 Titer and GMT (IU/mL) . 1.1 2354 931 1140 595 1875 1,000 541 318 335 1720 267 1200 116 1 2 154 : 870 136 ::. ••• + 635 100 1,000 . . 10 2 162029 HCS 100 10 ug 25 ug 50ug 10 ug 25 ug 50ug BHT ChulaCov19 Doses

27 30

N=12

74 75

N=11

76 **ABSTRACT:**

77 Background

- 78 Effective COVID-19 mRNA vaccines are mainly available in high-income countries. ChulaCov19,
- 79 a prefusion non-stabilized Spike protein-encoding, nucleoside-modified mRNA, lipid
- 80 nanoparticle encapsulated vaccine development, aims to enhance accessibility of mRNA
- 81 vaccine and future pandemic preparedness for low- to middle-income countries.

82 Methods

- 83 Seventy-two eligible volunteers, 36 aged 18-55 (adults) followed by 36 aged 56-75 (elderly)
- 84 enrolled in a dose escalation study of ChulaCov19 mRNA vaccine. Two doses of vaccine were

given 21 days apart at 10, 25, or 50 μg/dose (12/group). Safety was the primary and

- 86 immunogenicity the secondary outcome. Human convalescents' (HCS) and Pfizer/BioNTech
- 87 vaccinees' sera provided comparison panels.

88 Results

89 All three doses of ChulaCov19 were well tolerated and elicited robust dose-dependent and age-90 dependent B- and T-cell responses. Transient mild/moderate injection site pain, fever, chills, 91 fatigue, and headache were more common after the second dose. Four weeks after the second 92 ChulaCov19: dose at 10, 25, and 50 µg dose, MicroVNT-50 Geometric mean titer (GMT) against 93 wild-type was 848, 736 and 1,140 IU/mL, respectively, versus 267 IU/mL for HCS. All dose levels 94 elicited 100% seroconversion, with GMT ratio 4-8-fold higher than for HCS (p<0.01), and high 95 IFNy spot-forming cells/million peripheral blood mononuclear cells. The 50 µg dose induced 96 better cross-neutralization against Alpha, Beta, Gamma, and Delta variants than lower doses.

97 Conclusions

98	ChulaCov19 at 50 μ g/dose is well tolerated and elicited higher neutralizing antibodies than HCS
99	with strong T-cell responses. These antibodies cross neutralized four variants of concern and
100	ChulaCov19 has therefore proceeded to phase 2 and 3 clinical trials.
101 102	Trial registration number: ClinicalTrials.gov Identifier NCT04566276
103	
104	
105	
106	
107	
108	
109	
110	

112 INTRODUCTION

113	More than 10 billion doses of COVID-19 vaccines have been administered worldwide,
114	however only 10 % of those living in low-income countries received at least one dose (8
115	February 2022) ¹ . Among approved vaccines, mRNA vaccines have shown the highest efficacy ² .
116	Building capacity to develop and manufacture mRNA vaccines in low- to middle-income
117	countries (LMIC) is important for the current and future pandemics. The ChulaCov19 mRNA
118	vaccine (ChulaCov19) is a lipid nanoparticle (LNP) encapsulated nucleoside-modified mRNA,
119	encoding a non-stabilized, full-length SARS-Cov2 spike protein. Two major differences between
120	ChulaCov19 with the Pfizer/BioNTech and Moderna vaccines are that ChulaCov19 is not
121	prefusion stabilized and is encapsulated in a different LNP formulation. ChulaCov19 was
122	conceptualized in Thailand and initially manufactured in North America for early clinical
123	development, in parallel with large-scale production capacity development in Thailand. In
124	rodent and macaques, ChulaCov19 elicited strong B and T cells responses. The induced high
125	neutralizing antibody levels against wild-type virus were able to cross neutralize four variants of
126	concern (VOC). Here, we report a phase 1 open-label, dose-escalation study of ChulaCov19.
127	Methods:
128	Trial Design
129	This phase 1, open-label, dose escalation study to evaluate safety and immunogenicity

129 Inis phase 1, open-label, dose escalation study to evaluate safety and immunogenicity
 130 of ChulaCov19 vaccine enrolled healthy participants aged 18-55 (adults, n=36) followed by a
 131 cohort aged 56-75 (elderly, n=36). The inclusion and exclusion criteria are shown in the
 132 Supplemental Table S1. Both age cohorts received ChulaCov19 at 10, 25, or 50-µg per dose, 12
 133 participants per dose group for each age cohort, in a sentinel, dose-escalating manner.

The trial and the Investigational New Drug application were approved by the ethics committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, and Thailand's Food and Drug Administration, respectively. All participants provided written informed consent. The trial was conducted at the Chula Clinical Research Center and King Chulalongkorn Memorial Hospital, Bangkok.

139 Trial vaccine

ChulaCov19 mRNA was manufactured at Trilink Biotechnologies (San Diego, California),
and Integrity Bio Inc. (Camarillo, California). The encapsulating LNP formulation consists of four
lipid components with a proprietary ionizable ionized lipid developed by Genevant Sciences
Corporation (Vancouver, British Columbia). ChulaCov19 is stable at -75±10°C, -20±5°C, and,
importantly, 5±3°C for up to 6 months. ChulaCov19 was stored as a sterile suspension of 0.2
mg/ml at -75±10°C and diluted with normal saline according to the assigned dose, to be given
at 0.5 ml intramuscularly (IM).

147 **Trial procedures**

Four adult sentinel participants were enrolled to receive ChulaCov19 at 10-μg (IM). Once no halting criteria (**Table S2**) were reported by Day 3, the remaining eight 10-μg participants were enrolled. The same approach was followed for the 25- and 50-μg doses. The vaccine was administered in the deltoid muscle on Day 1 and Day 22±3, followed by 2 hours safety monitoring on-site. Enrollment of the elderly participants was commenced after DSMB review of the data when the last adult participant of the 10-μg group had reached Day 29 (one week after second vaccination) on study. A diary was provided to participants to record

155 solicited- and unsolicited adverse reactions, and concomitant medications for seven days.

156 Safety laboratory tests were performed at baseline, and days 8, 22, 29 and 50.

157 Assessment of safety and tolerability

Safety endpoints included solicited and unsolicited local adverse events (AE), systemic AE, use of antipyretics/analgesics in the seven days after vaccination, and serious adverse events (SAE) up to Day 50 (four weeks after second vaccination).

161 Assessment of immunogenicity

162 The binding to the SARS-CoV-2 S1 receptor-binding domain (RBD) was measured by 163 enzyme-linked immunosorbent assay (ELISA). Neutralizing antibody titers against wild-type and 164 VOC were assessed by live-virus microneutralization assay (MicroVNT-50) and pseudovirus 165 neutralization assay (PsVNT-50). SARS-Cov2 RBD-ACE2 blocking antibody was measured by 166 surrogate viral neutralization test. Cellular immunity was measured by IFNy-ELISpot assay 167 (ELISpot), and by intracellular cytokine staining (ICS) assay (Table S3). Tests were performed on 168 specimens collected at Days 1, 8, 22, 29 and 50; however, PsVNT-50 was performed only at 169 Days 29 and 50. Exploratory comparator serum panels included 30 human convalescents' 170 serum (HCS) from adults with COVID-19; serum samples were collected at four weeks after 171 confirmed diagnosis, and 27 Pfizer/BioNTech mRNA vaccinees; serum samples were collected at Day 29 (Table S4 and S5). 172

173 Statistical Analysis

Sample size for Phase I was based on practical and medical considerations, not power
for statistical hypothesis testing or precision of parameter estimation. Results of safety analyses
are presented as counts, percentages and group ages as mean (SD). Summary descriptive

statistics relevant for study endpoints were provided for each cohort and vaccine dose group atthe study time points indicated in the protocol.

179	Immunogenicity was analyzed based on the per protocol (PP) analysis set. Geometric
180	mean titers (GMT) and their 95%CI were calculated for MicroVNT-50, PsVNT-50, anti RBD-IgG,
181	anti S-Trimer, sVNT, IFNγ-ELISpot and Th1/Th2 spike-specific-CD4+ and CD8+ T-cells. Formal
182	comparisons of MicroVNT-50, PsVNT-50, anti RBD-IgG and sVNT against samples of 30 HCS from
183	adults with COVID-19 and 27 Pfizer/BioNTech mRNA vaccinees, were made using geometric
184	mean ratios (GMR 95%CI). Statistical analysis was conducted with Stata 15 (Statacorp LLC,
185	College Station, TX, USA).
186	Results:
187	Between 28 May 2021 and 2 July 2021, 132 individuals were screened of whom 36 were
188	enrolled in each age cohort (12 per dose group in each age cohort) (Figure S1 and S2). All but
189	one participant completed both vaccinations. The participant declining second vaccination was
190	from the adult 25-µg group and experienced moderate myalgia after the first vaccination,
191	which resolved within three days and which was accompanied by moderate CPK elevation but
192	normal cardiac enzymes, possibly related to strenuous physical labor. This participant was
193	excluded from the per protocol immunogenicity analysis as were two others: one participant
194	from the adult 10- μg group who was diagnosed with asymptomatic COVID-19 on the sixth day
195	after the second vaccination and one participant from the adult 50- μg group who had
196	confirmed positive baseline anti-RBD binding antibody test but was negative for SARS-CoV-2
197	molecular testing, indicating asymptomatic COVID-19 prior to enrolment. All participants
198	contributed to the safety analysis.

199 Characteristics of the study participants

- 200 Characteristics of the study participants are listed in Table 1. Mean age (SD) in the adult and
- 201 elderly cohorts was 35.8(9.1) and 65.1(5.4) years, respectively; body mass index was 23(2.8)
- and 23.3(3.3); and proportion of females was 67% and 53%.

Table 1: Demographic Characteristics of the participants by dose age groups

 $10 \mu g$ 25 µg 50 µg Characteristic Group Overall Group Group Adults (aged 18–55 years) N=12 N=12 N=12 N=36 Sex-number (%) Female 9 (75.0) 7 (58.3) 8 (66.7) 24 (66.7) 35.9 (5.9) 34.1 (9.0) 37.3 (11.8) 35.8 (9.1) Age-Mean (SD) 26-53 21-53 21-53 Min-max 21-44 Body-mass index (kg/m²), Mean (SD) 23.9(3.3) 22.1(2.6) 22.9 (2.5) 23.0 (2.8) Elderly (aged 56–75 years) N=12 N=12 N=12 N=36 Sex-number (%) Female 7 (58.3) 7 (58.3) 5 (41.7) 19 (52.8) Age-Mean (SD) 67.4 (3.2) 67.8 (3.2) 60 (5.5) 65.1(5.4) 64 - 73 65 - 74 56 -71 56 - 74 Min-max Body-mass index (kg/m²), Mean (SD) 24.1 (4.2) 22.7 (3.1) 23.2 (2.5) 23.3 (3.3)

204

205

206 Safety and Tolerability

207 *Local reactions* (Figure 1)

208 The most common local reaction was injection site pain. Its incidence was dose-dependent,

209 more common in adults than elderly, and after Dose 2. All local reactions were mild in the

elderly; some moderate events occurred in adults. All participants recovered after 2.79±1.7 and

211 1.91±0.9 days on average in adults and elderly after Dose 2, respectively. A single event of

severe erythema in the adult 10-µg group after Dose 2 resolved within 6 days.

213 *Systemic reactions* (Figure 1)

- 214 The three most common systemic reactions were fever, headache, and fatigue. Systemic
- reactions were more common at the 25-µg and 50-µg doses, after Dose 2, and in adults. Most
- reactions were mild to moderate and transient with mean duration 1.97±1.2 days in adults and
- 217 1.39±0.5 days in elderly after Dose 2.
- 218 Figure 1. Local and Systemic Adverse Events, by dose group and age cohorts. The 18-55- and
- 219 56-75-years old cohort is also referred to as adults and elderly.



220

221 Immunogenicity Results

222 SARS-CoV-2 Receptor Binding Domain (RBD) Antibody Responses (Figure 2a)

- 223 In the adult cohort, 4 weeks after second vaccination (Day50) the GMT of anti-RBD
- 224 antibody was significantly higher than for HCS 4 weeks after COVID-19 diagnosis with GMR of
- 225 3.78, 3.23, and 7.74, p≤0.01, respectively. In the elderly cohort, anti-RBD GMT were also dose-
- dependent but lower than observed in the adult cohort (Table S6). 226
- 227

228 Figure 2. SARS-CoV-2 Antibody-Binding and Neutralization Responses.



231 SARS-CoV-2 S-Spike Trimer Antibody Responses (Figure 2b)

232	In the adult cohort at Day 50, ChulaCov19 at 50-ug elicited highest anti-Spike-GMT at
233	24493.9 BAU/mL (p<0.01). In the elderly cohort, the anti-Spike GMT was lower than for the
234	adults at all three doses while anti Spike-GMT for the 50- μg dose was significantly higher than
235	for the 10-μg dose, p 0.001.
236	RBD-ACE2 Binding Inhibition Antibody Responses (sVNT)
237	GM of % RBD-ACE2 binding inhibition showed a dose-dependent pattern in both age-cohorts at
238	Day 29 but not at Day 50. All doses at Day 50 in both age-cohorts elicited GM>90% inhibition. %
239	Inhibition of the HCS and Pfizer/BNT vaccinee's (Day 29) panels was 76% and 93%, respectively
240	(Figure S3).
241 242	SARS-CoV-2-specific Live-virus Micro-Neutralization Tests (MicroVNT-50)
243	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of
243 244	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased
243 244 245	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 μ g doses (Figure 2c). In the adult cohort at Day50,
243 244 245 246	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 µg doses (Figure 2c). In the adult cohort at Day50, ChulaCov19 at 10, 25 and 50-µg doses induced significantly higher MicroVNT-50 GMT than HCS
243 244 245 246 247	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 µg doses (Figure 2c). In the adult cohort at Day50, ChulaCov19 at 10, 25 and 50-µg doses induced significantly higher MicroVNT-50 GMT than HCS at a ratio of 2.98, 2.59 and 4.01, respectively (p<0.01), whereas in the elderly cohort the values
243 244 245 246 247 248	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 µg doses (Figure 2c). In the adult cohort at Day50, ChulaCov19 at 10, 25 and 50-µg doses induced significantly higher MicroVNT-50 GMT than HCS at a ratio of 2.98, 2.59 and 4.01, respectively (p<0.01), whereas in the elderly cohort the values were: 0.48, 1.26and 2.09-folds, respectively. (Table S6). ChulaCov19 at 50-µg dose induced
243 244 245 246 247 248 249	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 µg doses (Figure 2c). In the adult cohort at Day50, ChulaCov19 at 10, 25 and 50-µg doses induced significantly higher MicroVNT-50 GMT than HCS at a ratio of 2.98, 2.59 and 4.01, respectively (p<0.01), whereas in the elderly cohort the values were: 0.48, 1.26and 2.09-folds, respectively. (Table S6). ChulaCov19 at 50-µg dose induced significantly higher MicroVNT-50 GMT against wild-type and 3 variants as compared to the 10-
243 244 245 246 247 248 249 250	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 µg doses (Figure 2c). In the adult cohort at Day50, ChulaCov19 at 10, 25 and 50-µg doses induced significantly higher MicroVNT-50 GMT than HCS at a ratio of 2.98, 2.59 and 4.01, respectively (p<0.01), whereas in the elderly cohort the values were: 0.48, 1.26and 2.09-folds, respectively. (Table S6). ChulaCov19 at 50-µg dose induced significantly higher MicroVNT-50 GMT against wild-type and 3 variants as compared to the 10- µg dose in both age cohorts while in the elderly cohort elicited MicroVNT-50 GMT were lower
243 244 245 246 247 248 249 250 251	Seroconversion rate on MicroVNT-50 in all dose groups reached 100% by Day50. GMT of the responses against WT virus were both dose- and age-dependent, and markedly increased from Day 29 to Day 50 for the 10, 25 and 50 µg doses (Figure 2c). In the adult cohort at Day50, ChulaCov19 at 10, 25 and 50-µg doses induced significantly higher MicroVNT-50 GMT than HCS at a ratio of 2.98, 2.59 and 4.01, respectively (p<0.01), whereas in the elderly cohort the values were: 0.48, 1.26and 2.09-folds, respectively. (Table S6). ChulaCov19 at 50-µg dose induced significantly higher MicroVNT-50 GMT against wild-type and 3 variants as compared to the 10- µg dose in both age cohorts while in the elderly cohort elicited MicroVNT-50 GMT were lower for all doses when compared to the adult cohort. (Figure 3a and Table S7).

253 *Pseudovirus Neutralization Tests*

- In the adult cohort, PsVNT-50 GMT (95% CI) of ChulaCov19 against WT at Day50 at 10, 25, 50-
- 255 μg and of HCS panel was 885.3, 902.9, 1,273.1, and 471.2, respectively. (Figure 2d). The GMT-
- 256 ratio of 50 μg dose/HCS was 2.7 (p=0.01). At Day 29, ChulaCov19 at 50-μg dose induced
- 257 significantly higher GMT than the Pfizer/BNT vaccinated panel against Alpha, Beta and Gamma
- variants at a ratio of 4.47, 11.94 and 4.23 (p=0.01), respectively (Figures 3b and Table S8). A
- new variant Omicron PsVNT-50 test results showed two-doses of ChulaCov19 at 50-µg has a
- significant decline of GMT against Omicron variant as compared to WT (Figure S4).
- 261
- 262
- 263 **Figure 3.** SARS-CoV-2 Neutralization Responses against variants of concern at Day 29 (4 weeks
- 264 after Dose2)



265

267 SARS-Cov2 Spike-specific T-Cell Responses

- At Day 29, all participants in the adult and elderly cohorts at 10-, 25-, and 50-μg showed strong
- 269 Spike-specific T-cell responses measured by IFNγ-ELISpot tests. The responses were lower in
- elderly at 10- and 25-ug than in adults (Figure 4a and Table S9). In adults, both Spike-specific
- 271 $IFN\gamma^{+}CD4^{+}$ and $IL2^{+}-CD4^{+}$ T-cell percentages were significantly higher in the 25- and 50-µg dose
- 272 recipients when compared to the 10-µg dose. (Table S10). ChulaCov19 elicited Spike-specific
- 273 Th1-dominated responses (Figure 4b).
- 274
- 275 **Figure 4:** SARS-Cov2 Wild-type Spike-specific T-cells responses



277 278

279

280 **Discussion**

281	To enhance access to effective COVID-19 mRNA vaccines in LMIC and to be prepared for
282	a next pandemic, complete mRNA-LNP vaccine development and manufacturing value chains
283	need to be established in LMICs. Unlike currently approved mRNA vaccines, such as Pfizer/BNT
284	and Moderna ³ , ChulaCov19 is a wild-type non-stabilized Spike-protein encoded mRNA vaccine
285	encapsulated with a different LNP and demonstrated thermostability at 2-8 ⁰ C for up to 6
286	months. In this phase 1 trial, three doses of ChulaCov19 vaccine were well tolerated with no
287	SAE observed in either age-group. Injection site pain is the most common AE while fever, chills,
288	headache, and myalgia were reported to be dose-dependent and more frequent after the
289	second dose. AEs were both less frequent and milder among the elderly participants. Moderate
290	to severe events were rare overall and all AEs resolved on average 2.5 days.
291	The results indicated that this LNP-encapsulated non-di-Proline-stabilized Spike-protein mRNA
292	vaccine is strongly immunogenic. ChulaCov19 at 50- μg dose induced high SARS-CoV2-binding
293	and neutralizing antibodies one week after dose 2 (p<0.01) with a microVNT-50 GMT 6-fold
294	higher than for HCS. At 4 weeks after dose 2, there was a further rise of all tested antibodies
295	and all 3 doses elicited microVNT-50 GMT higher than HCS with a GMT ratio of 4-8-fold
296	(p<0.01). The 50- μg dose induced higher micro-VNT-50 and psVNT-50 GMT against tested
297	variants than the lower doses (p<0.01). In the adult cohort, at one week after Dose 2, the ratios
298	of ChulaCov19 50- μg dose elicited psVNT-50 GMT against Alpha, Beta, and Gamma variants
299	that were 4.5, 11.9 and 4.2, respectively higher compared to Pfizer/BNT vaccine(p<0.01). In
300	term of Omicron variant, ChulaCov19 vaccine, as reported in approved Covid-19 mRNA vaccine,

All doses of ChulaCov19 generated strong T cell responses and the higher doses (25 and 50-µg)

2-doses vaccination may not effective against Omicorn variant, a Third dose is required⁴.
Developing pan-SARS-Cov2 or pan-Coronavirus vaccine against future pandemic by is
warranted⁵.

304

305 elicited higher % of Spike-specific IL2+CD4+T-cells and % of IFNy+CD4+T-cells than the 10-µg 306 dose (p<0.01 and p<0.05, respectively). All doses ChulaCov19 elicited predominantly SARS-CoV2-specific Th1-type responses. Based on these results, the DSMB has recommended that 307 308 ChulaCov19 be further advanced to a phase 2 randomized-controlled trial with the 50-µg dose. 309 This vaccine did not contain prefusion stabilization of Spike with 2 prolines (K986P/V987P) that many approved COVID-19 vaccine platforms use⁶. The Phase I data 310 311 presented here show ChulaCov19 elicited robust humoral and T cell responses, which are often 312 greater than the BioNTech/Pfizer vaccine that contains the di-proline modification. There are other differences in the BioNTech/Pfizer modified mRNA vaccine that could account for the 313 314 greater potency of ChulaCov19, including different UTRs, coding sequence optimization, poly(A) 315 tail, and the LNP formulation used. Our data does support that the Spike does not need to be prefusion stabilized to induce a potent and protective response, unlike RSV⁷. 316

Recent studies suggest that a GMT-ratio of neutralizing or binding antibody in vaccinees to the level in convalescent patients of >1 is associated with >70% vaccine efficacy rate (VE).² In addition, higher binding and neutralizing antibody levels at four weeks after the second dose were found to correlate with symptomatic infection risk reduction in the AZD1222 trial⁸ and COVE study⁹. ChulaCov19 induced strong binding and neutralizing antibody responses four weeks after the second dose and the ratio of neutralizing antibody GMT in ChulaCov19

323 vaccinees vs convalescent sera of four weeks after diagnosis of approximately four to eight 324 folds suggests that this vaccine candidate has a potentially significant vaccine efficacy. A consensus on correlates of protection may be achieved soon¹⁰ and recently the International 325 326 Coalition of Medicines Regulatory Authorities (ICMRA) has accepted well-designed immunobridging studies for authorizing COVID-19 vaccines¹¹. 327 328 Accessibility to effective COVID-19 vaccines, particularly mRNA vaccines, remains very limited in many low-middle income countries (LMICs)¹². The main goal of ChulaCov19 329 development is to be part of the solution for LMICs. There are several challenges to overcome: 330 331 the speed of clinical development to reach emergency use authorization (EUA), the speed of 332 establishing large scale manufacturing capacity, negotiation of expanding LNP-licensing 333 territory, and the cost and long lead-time raw materials. Currently Bionet Asia, Thailand has 334 already established manufacturing capacity for both mRNA production and encapsulation, and 335 a first clinical lot has been released for further clinical development and EUA approval. 336 The limitations of this study include: the sample size is small due to the phase 1 337 uncontrolled dose-finding design. The exploratory comparative immunogenicity analyses with 338 convalescent sera or Pfizer/BNT vaccinees' sera are not direct head-to-head comparisons and 339 can contain bias. Convalescent sera were collected during the rise of the Delta variant outbreak, 340 and possibly antibody responses are stronger against Delta than WT. To minimize bias, the 341 convalescent and Pfizer/BNT vaccinees' serum samples were tested at the same laboratories 342 together with the ChulaCov19 vaccinated samples. In addition, a RCT phase 2 study has 343 commenced and a larger scale immune-bridging, non-inferiority phase 3 study is planned. 344

- 345 In summary, ChulaCov19 mRNA vaccine is well tolerated and elicited strong SARS-CoV2
- 346 specific B- and T-cell immunogenicity and is currently under Phase 2 and later clinical
- 347 development.
- 348
- 349 <u>References</u>
- 1. Coronavirus Pandemic (COVID-19) Vaccinations. Our World in Data, 2020. at
- 351 <u>https://ourworldindata.org/coronavirus.</u>)
- 352 2. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive
- of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine 2021;27:1205-
- 354 11.
- 355 3. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases:
- 356 principles, delivery and clinical translation. Nat Rev Drug Discov 2021;20:817-38.
- 357 4. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA
- 358 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and
- 359 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -
- 360 VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep
- 361 2022;71:139-45.
- 362 5. Saunders KO, Lee E, Parks R, et al. Neutralizing antibody vaccine for pandemic and pre-
- 363 emergent coronaviruses. Nature 2021;594:553-9.
- 364 6. Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A,
- 365 Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral
- 366 Variants. Front Immunol 2021;12:701501.

- 367 7. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein
- 368 vaccine for respiratory syncytial virus. Science 2013;342:592-8.
- 369 8. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-40.
- 371 9. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the
- 372 mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv 2021.
- 373 10. Koup RA, Donis RO, Gilbert PB, Li AW, Shah NA, Houchens CR. A government-led effort
- to identify correlates of protection for COVID-19 vaccines. Nat Med 2021;27:1493-4.
- 375 11. Access Consortium: Alignment with ICMRA consensus on immunobridging for
- authorising new COVID-19 vaccines. 2021.
- 377 12. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations.

378 Nat Hum Behav 2021;5:947-53.

379

380 Acknowledgement

- 381 This study was funded by National Vaccine Institute (NVI), grant no. 2563. 1/11 and 2564.1/4;
- 382 Chulalongkorn University Second Century Fund (C2F); the Ratchadapisek Sompoch Endowment
- 383 Fund (2021), Chulalongkorn University (764002-HE04); and Public Donation through Covid-19
- 384 vaccine development fund of the Faculty of Medicine, Chulalongkorn University and the Thai
- Red Cross Society, Thailand. The authors would like to thank all the study participants without
- 386 whose support the study would not have been possible.